Yourgene Health products

Elucigene DPYD assay is a simple genotyping test that can identify patients with DPD deficiency allowing an alternative treatment to be offered. 5-fluorouracil (5-FU) is a chemotherapy agent used to treat a range of cancers including colorectal, head and neck, breast, pancreatic and stomach cancer. 5-FU is metabolized by the dihydropyrimidine dehydrogenase enzyme (DPD) which is encoded by the DPYD gene. Several variants within DPYD have been described that lead to reduced or abolished DPD activity. Patients with these variants are at an increased risk of severe or fatal 5-FU toxicity. Therefore, implementation of DPD deficiency screening by genotyping will allow a more accurate prediction of toxicity and chemotherapeutic response.